Weekly Report ·

Strategic Signals Weekly

Licensing deals, strategic reviews, and financing events from regulatory filings. Part of the RxDataLab platform: clinical trials, SEC filings, and hedge fund positioning, linked by company.

Get access Live dashboard →

Get in Touch

Interested in this coverage?

Reach out with questions or to discuss what you're tracking.

or email [email protected]

16
Total Signals
1
Licensing Deals
1
Strategic Reviews
1
FDA Actions (CRL)
0
PDUFA Dates

Weekly Signal Volume

Licensing Strategic CRL Financing PDUFA This week

FDA Actions (CRL)

Companies that received a Complete Response Letter from the FDA, indicating a drug application was not approved in its current form.

FiledCompany
Feb 17
Disc Medicine, Inc. (IRON)
...conference call at 8:00 AM ET to discuss the Complete Response Letter issued by the U.S. Food and Drug Administration on February 13, 2026 with respect to the Company's New Drug Application for bitopertin as a treatment for patients with erythropoietic protoporphyria.... [SEC]

Strategic Reviews

Companies exploring strategic alternatives, potential M&A, or board-level reviews.

FiledCompany
Feb 23
Genprex, Inc. (GNPX)
...prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including... [SEC]

Licensing & Partnerships

New collaboration agreements, licensing deals, and partnership announcements.

FiledCompany
Feb 18
Theriva Biologics, Inc. (TOVX)
...(the "Company") entered into a license agreement (the "Agreement") with Rasayana Therapeutics, Inc. ("Rasayana"), whereby the Company granted Rasayana an exclusive worldwide license with the right to grant sublicenses to Research, Develop,... [SEC]

Financing Events

Capital raises, ATM programs, debt offerings, and other financing activities.

FiledCompany
Feb 23
Candel Therapeutics, Inc. (CADL)
$93.5M public offering [SEC]
Feb 23
ADC Therapeutics SA (ADCT)
public offering [SEC]
Feb 20
ATOSSA THERAPEUTICS, INC. (ATOS)
atm [SEC]
Feb 20
ORAMED PHARMACEUTICALS INC. (ORMP)
private placement [SEC]
Feb 19
COMPASS Pathways plc (CMPS)
$150.0M public offering [SEC]
8 more on the RxDataLab platform

About This Data

These events are extracted from SEC 8-K filings using keyword detection across the full filing text. Summaries are generated automatically from the filing content to describe what happened in plain language. We track five categories:

  • FDA Actions (CRL): Companies that received a Complete Response Letter from the FDA, the agency's formal notice that a drug application cannot be approved as submitted.
  • PDUFA Dates: Upcoming FDA decision deadlines disclosed via 8-K. A PDUFA date is the statutory deadline by which the FDA must complete its review of a new drug application.
  • Strategic Reviews: Companies disclosing that they are exploring "strategic alternatives," potential sales, or board-level reviews of company direction.
  • Licensing Deals: Material definitive agreements involving licensing, collaboration, or partnership arrangements. Requires multiple keyword matches to reduce noise.
  • Financing Events: Capital raises, ATM offerings, registered direct transactions, and debt issuances. Filing proceeds are extracted where disclosed.

On the RxDataLab platform, each event is cross-referenced with the company's clinical trial pipeline, insider trading activity, and financials.

Data from RxDataLab and SEC EDGAR.